Preferential expression of Th2-type chemokine and its receptor in atopic dermatitis

被引:44
作者
Uchida, T
Suto, H
Ra, C
Ogawa, H
Kobata, T
Okumura, K [1 ]
机构
[1] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan
[2] Juntendo Univ, Sch Med, Allergy Res Ctr, Tokyo 1138421, Japan
[3] Juntendo Univ, Sch Med, Dept Dermatol, Tokyo 1138421, Japan
[4] Dokkyo Univ, Sch Med, Inst Med Sci, Div Immunol, Mibu, Tochigi 321293, Japan
关键词
atopic dermatitis; chemokine; chemokine receptor; T(h)1; T(h)2;
D O I
10.1093/intimm/dxf109
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Lesional skin of patients with atopic dermatitis (AD) is histologically characterized by hypertrophy of the skin, and the infiltration of a large number of eosinophils and T cells into the dermis. Recent studies have indicated that T(h)2 cells play a crucial role in the pathogenesis of AD skin. Chemokines and their receptors are implicated in the development of symptoms of various skin diseases such as AD and psoriasis vulgaris (psoriasis). We have examined the in situ expression of a typical T(h)2-type chemokine, thymus- and activation-regulated chemokine (TARC), and its receptor (CCR4) using immunohistochemical techniques. TARC was found to be highly expressed in the basal epidermis of the lesional skin of AD patients and only slightly in the non-lesional skin. On the other hand, no positive cells were seen in the lesional skin of psoriasis. Consistently, CCR4(+) cells were present predominantly in the lesional skin of AD patients, but not in the non-lesional skin. In contrast, in the lesional skin of psoriasis patients, cells positive for CCR5, which is expressed on T(h)1 cells, were abundantly present. Interestingly, psoralen plus ultraviolet A therapy reduced the number of CCR4(+) cells in the AD skin lesions. These results suggest that T(h)2-type cytokines such as TARC are involved in the pathogenesis of skin lesions in AD patients through the preferential recruitment of T(h)2 cells.
引用
收藏
页码:1431 / 1438
页数:8
相关论文
共 63 条
[1]  
AIKAWA Y, 1997, JPN J DERMATOL, V107, P1473
[2]  
[Anonymous], ACTA DERM VENERE S92, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]
[3]   Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s [J].
Bonecchi, R ;
Bianchi, G ;
Bordignon, PP ;
D'Ambrosio, D ;
Lang, R ;
Borsatti, A ;
Sozzani, S ;
Allavena, P ;
Gray, PA ;
Mantovani, A ;
Sinigaglia, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) :129-134
[4]   Chemokine IP-10 expression in cultured human keratinocytes [J].
Boorsma, DM ;
Flier, J ;
Sampat, S ;
Ottevanger, C ;
de Haan, P ;
Hooft, L ;
Willemze, R ;
Tensen, CP ;
Stoof, TJ .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1998, 290 (06) :335-341
[5]   The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells [J].
Campbell, JJ ;
Haraldsen, G ;
Pan, J ;
Rottman, J ;
Qin, S ;
Ponath, P ;
Andrew, DP ;
Warnke, R ;
Ruffing, N ;
Kassam, N ;
Wu, L ;
Butcher, EC .
NATURE, 1999, 400 (6746) :776-780
[6]   Characterization of gene expression in resting and activated mast cells [J].
Chen, HX ;
Centola, M ;
Altschul, SF ;
Metzger, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (09) :1657-1668
[7]  
D'Ambrosio D, 1998, J IMMUNOL, V161, P5111
[8]   Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes [J].
Forssmann, U ;
Uguccioni, M ;
Loetscher, P ;
Dahinden, CA ;
Langen, H ;
Thelen, M ;
Baggiolini, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 185 (12) :2171-2176
[9]  
Furue Masutaka, 1994, Journal of Dermatological Science, V7, P89, DOI 10.1016/0923-1811(94)90081-7
[10]   Functional expression of the eotaxin receptor CCR3 in T lymphocytes co-localizing with eosinophils [J].
Gerber, BO ;
Zanni, MP ;
Uguccioni, M ;
Loetscher, M ;
Mackay, CR ;
Pichler, WJ ;
Yawalkar, N ;
Baggiolini, M ;
Moser, B .
CURRENT BIOLOGY, 1997, 7 (11) :836-843